QurAlis Grants Lilly Exclusive Global License for QRL-204, a Potentially First-in-Class Precision Therapy That Restores UNC13A Function in ALS and FTD

QRL-204 is a splice-switching ASO generated through QurAlis’ FlexASO™ Platform; represents Lilly’s first program targeting UNC13A in ALS and FTD Parties to also collaborate to leverage QurAlis’ ALS and ASO development expertise to advance QRL-204 and next-generation compounds UNC13A is an…